Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group

Clinical Infectious Diseases

Volumn 37, Issue 4, 2003, Pages 551-558

  Spritzler, John ^a   Mildvan, Donna ^b   Russo, Aleksandra ^a   Asthana, Desh ^d   Livnat, Daniella ^e   Schock, Barbara ^c   Kagan, Jonathan ^e   Landay, Alan ^f   Haas, David W ^g,h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0042943096     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376986     Document Type: Article

References (54)

1. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
2. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
4. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. New Engl J Med 1996; 335:1091-8.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl J Med 1997; 337:725-33.
6. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998; 4:208-14.
7. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
8. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
9. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40-7.
10. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-50.
11. Kaufmann GR, Zaunders J, Cooper DA. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect 1999; 75:218-24.
12. + cell counts despite persistently detectable HIV load. New Engl J Med 1998; 338:1074-5.
13. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351:723-4.
14. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76.
15. Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. AIDS 1999; 13:525-6.
16. Fessel WJ, Krowka JF, Sheppard HW, et al. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. J AIDS 2000; 23:314-20.
17. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-69.
18. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Monterey, CA: Wadsworth & Brooks/Cole Advanced Books & Software, 1984.
19. 8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Immunol Lett 1999; 66:105-10.
20. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70.
21. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12:1833-44.
22. Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13:951-6.
23. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-35.
24. + T cell kinetics and activation in human immunodeficiency virus- infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-23.
25. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-8.
26. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183:1009-16.
27. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002; 185:1578-85.
28. D'Ettorre G, Forcina G, Andreotti M, et al. Discordant response to antiretroviral therapy: HW isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS 2002; 16:1877-85.
29. Pitrak DL, Bolanos J, Hershow R, Novak RM. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001; 15:1317-9.
30. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
31. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
32. Ortigao-de-Sampaio MB, Abreu TF, Linhares-de-Carvalho MI, Ponce de Leon A, Castello-Branco LR. Surrogate markers of disease progression in HIV-infected children in Rio de Janeiro, Brazil. J Trop Pediatr 1999; 45:299-502.
33. Plaeger S, Bass HZ, Nishanian P, et al. The prognostic signifcance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol 1999; 90:238-46.
34. Fahey JL. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol 1998; 5:597-603.
35. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:318-26.
36. + lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998; 12:1267-73.
37. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999; 13:1077-81.
38. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000; 182:96-103.
39. Levacher M, Bouscarat F, Landman R, et al. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudihe, didanosine, and ritonavir. AIDS Res Human Retroviruses 2000; 16:1869-75.
40. Badley AD, Parato K, Cameron DW, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6:420-32.
41. Franco JM, Rubio A, Rey C, et al. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Europ J Clin Microbiol Infect Dis 1999; 18:733-6.
42. + T lymphocytes in a cohort of HIV type 1-infected parents treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. AIDS Res Hum Retroviruses 1999; 15:963-72.
43. Seth A, Markee J, Hoering A, et al. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy. J Infect Dis 2001; 183:722-9.
44. Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with β2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64-75.
45. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. New Engl J Med 1990; 322:166-72.
46. Fahey JL, Taylor JM, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998; 12:1581-90.
47. 4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis 1998; 178:423-30.
48. Zangerle R, Steinhuber S, Sarcletti M, et al. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol 1998; 116:228-39.
49. Martinez-Bru C, Cortes M, Planella T, et al. Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. Ann Clin Biochem 1999; 36:601-8.
50. Pakker NG, Kroon ED, Roos MT, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999; 13:203-12.
51. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000; 14:2823-9.
52. + T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6:904-12.
53. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996; 26:1-7.
54. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.